- Division of Translational and Clinical Sciences – DTCS
- Oncology 2 – Translational Clinical – OTC
- Study Section:
- Drug Discovery and Molecular Pharmacology – DMP
Dr. Jeffrey Smiley is Scientific Review Officer for the Drug Discovery and Molecular Pharmacology Study Section in CSR’s Oncology Translational and Clinical Integrated Review Group.
Dr. Smiley received a Ph.D. in biochemistry from the University of North Carolina -– Chapel Hill. His research there focused on the catalytic mechanism of OMP decarboxylase, a key enzyme in pyrimidine metabolism. He then carried out post-doctoral research at Penn State University, investigating recombinant catalytic antibodies. Dr. Smiley spent 11 years on the faculty at Youngstown State University, carrying out further research on OMP decarboxylase, as well as other decarboxylases, with funding from NIH and other sources. He then began a career in grants management as a program manager at the American Chemical Society Office of Research Grants, overseeing proposals in organic chemistry and related fields for the Petroleum Research Fund, as well as managing the new Teva USA Scholars Program for research in medicinal chemistry.